Mylan vs. FDA (And Ranbaxy): Diovan Exclusivity Forfeiture Edition
This article was originally published in The Pink Sheet Daily
Executive Summary
In a suit against FDA, Mylan argues that Ranbaxy’s delay in getting tentative approval for its valsartan ANDA within 30 months of submission triggered forfeiture of its 180-day marketing exclusivity.